C Diff Treatment

C Diff Treatment

1249 bookmarks
Custom sorting
The Prevalence of Clostridium difficile Colitis and Effect on All-Cause Mortality in Elderly Patients after Hip Fracture Surgery: A Korean Nationwide Cohort Study
The Prevalence of Clostridium difficile Colitis and Effect on All-Cause Mortality in Elderly Patients after Hip Fracture Surgery: A Korean Nationwide Cohort Study
The prevalence of CDC after hip fracture surgery in elderly patients was 1.43%. CDC after hip fracture in the elderly patients significantly increased the all-cause mortality rate after discharge.
·pubmed.ncbi.nlm.nih.gov·
The Prevalence of Clostridium difficile Colitis and Effect on All-Cause Mortality in Elderly Patients after Hip Fracture Surgery: A Korean Nationwide Cohort Study
The central role of the gut in intensive care | Critical Care | Full Text
The central role of the gut in intensive care | Critical Care | Full Text
Critically ill patients undergo early impairment of their gut microbiota (GM) due to routine antibiotic therapies and other environmental factors leading to intestinal dysbiosis. The GM establishes connections with the rest of the human body along several axes representing critical inter-organ crosstalks that, once disrupted, play a major role in the pathophysiology of numerous diseases and their complications. Key players in this communication are GM metabolites such as short-chain fatty acids and bile acids, neurotransmitters, hormones, interleukins, and toxins. Intensivists juggle at the crossroad of multiple connections between the intestine and the rest of the body. Harnessing the GM in ICU could improve the management of several challenges, such as infections, traumatic brain injury, heart failure, kidney injury, and liver dysfunction. The study of molecular pathways affected by the GM in different clinical conditions is still at an early stage, and evidence in critically ill patients is lacking. This review aims to describe dysbiosis in critical illness and provide intensivists with a perspective on the potential as adjuvant strategies (e.g., nutrition, probiotics, prebiotics and synbiotics supplementation, adsorbent charcoal, beta-lactamase, and fecal microbiota transplantation) to modulate the GM in ICU patients and attempt to restore eubiosis.
·ccforum.biomedcentral.com·
The central role of the gut in intensive care | Critical Care | Full Text
Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort - Preethi G. Venkat, Nghia H. Nguyen, Jiyu Luo, Alexander S. Qian, Sahil Khanna, Siddharth Singh, 2022
Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort - Preethi G. Venkat, Nghia H. Nguyen, Jiyu Luo, Alexander S. Qian, Sahil Khanna, Siddharth Singh, 2022
·journals.sagepub.com·
Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort - Preethi G. Venkat, Nghia H. Nguyen, Jiyu Luo, Alexander S. Qian, Sahil Khanna, Siddharth Singh, 2022
Comparison of Length of Hospital Stay for Community-Acquired Infections Due to Enteric Pathogens, Influenza Viruses and Multidrug-Resistant Bacteria: A Cross-Sectional Study in Hungary - PubMed
Comparison of Length of Hospital Stay for Community-Acquired Infections Due to Enteric Pathogens, Influenza Viruses and Multidrug-Resistant Bacteria: A Cross-Sectional Study in Hungary - PubMed
Community-acquired infections (CAI) can affect the duration of care and mortality of patients. Therefore, we aimed to investigate these as well as factors influencing the length of hospital stay in patients with CAI due to enteric pathogens, influenza viruses and multidrug-resistant (MDR) bacteria. …
·pubmed.ncbi.nlm.nih.gov·
Comparison of Length of Hospital Stay for Community-Acquired Infections Due to Enteric Pathogens, Influenza Viruses and Multidrug-Resistant Bacteria: A Cross-Sectional Study in Hungary - PubMed
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
C. difficile infection isn't without long-term concerns. Why preserving gut microbiome richness is vital in managing C. difficile infection and how to deal with it https://t.co/7n25c460dp #GMFH10Years— GutMicrobiota Health (@GMFHx) December 9, 2022
·twitter.com·
GutMicrobiota Health on Twitter
Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PubMed
Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PubMed
The 2021 focused update to the Infections Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines for management of Clostridioides difficile infection (CDI) prioritizes the use of fidaxomicin over vancomycin for the treatment of initial and recurrent …
·pubmed.ncbi.nlm.nih.gov·
Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PubMed
MTIG on Twitter
MTIG on Twitter
Dysbiosis secondary to antibiotic exposure leads to vulnerability to #CDiff with recurrent disease occurring in a significant subset of patients. #Microbiome therapeutics are currently in development that have the potential to help. pic.twitter.com/jJwPascsKQ— MTIG (@MTIG_News) December 8, 2022
·twitter.com·
MTIG on Twitter
Initial Therapy Matters for Clostridioides difficile – Get it Right the First Time - OverView
Initial Therapy Matters for Clostridioides difficile – Get it Right the First Time - OverView
Although C. difficile infection has historically been considered a hospital-acquired infection, it is now common in the community settings. Therefore, internal medicine physicians and primary care providers need to be well-versed not only in the diagnosis, but also in the selection of therapy for C, difficile infection. To reduce severe or recurrent C. difficile infection, and C. difficile- associated hospitalizations, physicians must promptly recognize the signs and symptoms of C. difficile infection, identify patients at high risk for recurrence, and select the most treatments while working collaboratively with specialists to improve patient outcomes.
·achlcme.org·
Initial Therapy Matters for Clostridioides difficile – Get it Right the First Time - OverView
#GMFH2023 has an excellent program in store for you. Don’t miss it! ✅ Next-generation probiotics: single strains and consortia ✅ Fecal microbiota transplantation ✅ Diet and prebiotics ✅ Microbiota-derived molecules @esnm_eu @AmerGastroAssn
#GMFH2023 has an excellent program in store for you. Don’t miss it! ✅ Next-generation probiotics: single strains and consortia ✅ Fecal microbiota transplantation ✅ Diet and prebiotics ✅ Microbiota-derived molecules @esnm_eu @AmerGastroAssn
#GMFH2023 has an excellent program in store for you. Don’t miss it!✅ Next-generation probiotics: single strains and consortia✅ Fecal microbiota transplantation✅ Diet and prebiotics✅ Microbiota-derived molecules@esnm_eu @AmerGastroAssn https://t.co/5u0d4X8K5r— GutMicrobiota Health (@GMFHx) December 8, 2022
·twitter.com·
#GMFH2023 has an excellent program in store for you. Don’t miss it! ✅ Next-generation probiotics: single strains and consortia ✅ Fecal microbiota transplantation ✅ Diet and prebiotics ✅ Microbiota-derived molecules @esnm_eu @AmerGastroAssn
Outcomes of Patients Who Developed Clostridioides difficile Infection During Hospitalization and Had a History of Comorbid Post-Traumatic Stress Disorder - Cureus
Outcomes of Patients Who Developed Clostridioides difficile Infection During Hospitalization and Had a History of Comorbid Post-Traumatic Stress Disorder - Cureus
Introduction: Clostridioides difficile (C. difficile), is a common cause of nosocomial diarrhea. Antibiotic use is a risk factor for developing C. difficile infection (CDI). Clinical presentatio...
·news.google.com·
Outcomes of Patients Who Developed Clostridioides difficile Infection During Hospitalization and Had a History of Comorbid Post-Traumatic Stress Disorder - Cureus
Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC
Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC
Acute diarrhea is a common and debilitating complication in recipients of an allogeneic hematopoietic stem cell transplantation (HCT). In this prospective, observational, and multi-center study we examined all episodes occurring in the first 6 months of 142 consecutive adult patients who underwent a …
·pubmed.ncbi.nlm.nih.gov·
Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines
Clostridioides difficile infection (CDI) remains a significant clinical challenge both in the management of severe and severe-complicated disease and the prevention of recurrence. Guidelines released by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America (ID …
·pubmed.ncbi.nlm.nih.gov·
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines
Novel Biome on Twitter
Novel Biome on Twitter
It is important to remember that for donor microbiota to thrive and survive in an entirely new environment is no simple feat, so it the best chance by reducing barriers of engraftment in the recipient’s gut via pre-treatment with antibiotics is a logical step. #fmt #guthealth pic.twitter.com/01CFu4YmfR— Novel Biome (@NovelBiome) November 23, 2022
·twitter.com·
Novel Biome on Twitter
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
Can we use existing drugs any better? @bhmullish highlights major strengths and caveats of fidaxomicin and rifamixin in terms of efficacy and side effects@esnm_eu #GMFHCoverage pic.twitter.com/fwY06YFnRc— GutMicrobiota Health (@GMFHx) November 22, 2022
·twitter.com·
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
.@bhmullish: Ridinilazole is a new drug with some limitations in C. difficile management such as more recurrence compared to vancomycin. However, ridinilazole is more associated with preservation of gut @esnm_eu #GMFHCoverage pic.twitter.com/nSFLJVCJsC— GutMicrobiota Health (@GMFHx) November 22, 2022
·twitter.com·
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
“.@bhmullish also summarizes available approaches for preventing C. difficile infection including probiotics, anti-CDI antibiotics and ribaxamase. @esnm_eu #GMFHCoverage”
·twitter.com·
GutMicrobiota Health on Twitter
Can C. DIff. Cause Long Term Problems?
Can C. DIff. Cause Long Term Problems?
Are you having ongoing digestive problems like diarrhea and cramping pain? If you are wondering if a recent C. diff. infection can cause problems like this,  then you're in the right place.  In this article we look at this topic.  The impact of c. diff. in causing long-term chronic digestive issues.  This is another form of post-infectious IBS.  Research Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296708/ Florastor probiotic (Affiliate link): https://geni.us/kknw0f (Amazon) Pure GG (Affiliate link): https://geni.us/z5faaBV (Amazon) Saccharomyces boulardi (Affilate link): https://geni.us/FQC13DA (Amazon) C. diff. also known as clostridium difficile can cause massive digestive tract disturbances like diarrhea, dehydration, cramping, and pain.  It can even lead to systemic symptoms like fever, body, aches, and chills in a similar way as a cold or flu.  The clostridium difficile bacteria can actually be part of our normal digestive flora like the  "good commensal bacteria."  When it is allowed to grow unchecked by the other good bacteria in your microbiome, it can get out of control in a sense.  This bacteria typically lives in harmony with the other bacteria in our microbiome.  Not everybody has it in their digestive tract but a lot of people do often it is in relative balance with the other microbes.  It even supports the digestive cells and contributes to our overall digestive health.  This is what happens when it's in normal or small amounts in our digestive tract.  Typically the problems from this microbe arise when we take antibiotics.   The reason for taking the antibiotic could be any really.  Those antibiotics start to reduce the number of the good bacteria.  These are in competition with the clostridium difficile or c. diff. bacteria constantly.  When some of those get wiped out, the c. diff. has the ability to emerge, grow, and expand its territory.  They will expand outside of the small territory that was supportive for our digestive tract.  Once this happens there are too many of them to keep in check leading to many problems.  This is when we start to have major digestive symptoms.  So the antibiotics reduce your good bacteria.  The c. diff. does not get weakened by the antibiotics depending on which one it is.  It is just not sensitive to many of them.  Meanwhile the good bacteria are dying off.  As they are trying to come back and recover, the c diff is expanding and expanding. While they're expanding, they're also producing a toxin.  That toxin can cause your immune system to respond and cause a lot of internal inflammation in the digestive tract.  Also what happens is you get increased water flooding into that digestive tract to flush out that toxin.  When that happens that's when you get the uncontrolled diarrhea.  Once it's treated with either vancomycin or metronidazole, that c diff will recede.  With this you will become less symptomatic.  However this microbe is fairly crafty and can easily form spores.  Those spores are basically like a capsule that protects the internal DNA and the overall structure of the bacteria.  It doesn't allow the antibiotics to affect them.  When in the spore formation the bacteria are basically in a hibernated state.  Once you are done taking that antibiotic and it flushes through your system, that c diff can start to re-emerge again.  Depending on the overall quantities that are there, and what's going on with your good bacteria, they can start gaining territory again.  With this they will produce more of this toxin.  Once that shifts to a point where the toxin is stimulating your immune system, it will cause increased fluid to come in.  Depending on how much of that toxin the c diff producing, determines if you have diarrhea again. So does C. diff. cause long-term problems? Yes, it can if it's not eradicated with that first or second round or antibiotics or goes unnoticed.  You may have less severe symptoms than initially but they can still be there.  There are some studies looking  at the rates of digestive problems following a C. diff. infection.  They found that there's much higher rates of digestive problems in people whom previously had a C. diff. infection. This lasted for up to 12 months following that original infection.  In fact, the study participants were eight times more likely to be readmitted to the hospital for another digestive problem.  That persisted for up to 12 months.  There's also more general digestive issues like IBS symptoms that can persist for even longer 24 months or possibly even a longer time period.  This is just another form of post-infectious IBS.  When you have this there are lingering amounts of the microbe there and either the immune system, the antibiotic, or the local environment has not been able to keep it in check.  It's the persistence of that microbe and the overall long-term damage that happens from that microbe that creates this increased risk for ongoing problems.
·t.co·
Can C. DIff. Cause Long Term Problems?
RT @ruth_abx: Some excellent webinars and videos available from the members of @WelshAbx in support of #WAAW . #IVOST #cdiff #KeepAntibioti…
RT @ruth_abx: Some excellent webinars and videos available from the members of @WelshAbx in support of #WAAW . #IVOST #cdiff #KeepAntibioti…
Some excellent webinars and videos available from the members of @WelshAbx in support of #WAAW . #IVOST #cdiff #KeepAntibioticsWorking @CV_Pharmacy https://t.co/KwO3Ec0E1O— Ruth (@ruth_abx) November 18, 2022
·twitter.com·
RT @ruth_abx: Some excellent webinars and videos available from the members of @WelshAbx in support of #WAAW . #IVOST #cdiff #KeepAntibioti…
Phage therapy for Clostridioides difficile infection
Phage therapy for Clostridioides difficile infection
Clostridioides difficile is endemic in the intestinal tract of healthy people. However, it is responsible for many healthcare-associated infections, such as nosocomial diarrhea following antibiotic treatment. Importantly, there have been cases of unsuccessful treatment and relapse related to …
·pubmed.ncbi.nlm.nih.gov·
Phage therapy for Clostridioides difficile infection
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
Objective To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with irritable bowel syndrome (IBS). Design A PubMED-based literature review of mechanisms and treatment of IBS was conducted independently by the two authors, and any differences of perspective or interpretation of the literature were resolved following discussion. Results The availability of several noninvasive clinical tests can appraise the mechanisms responsible for symptom generation in IBS, including rectal evacuation disorders, abnormal transit, visceral hypersensitivity or hypervigilance, bile acid diarrhoea, sugar intolerances, barrier dysfunction, the microbiome, immune activation and chemicals released by the latter mechanism. The basic molecular mechanisms contributing to these pathophysiologies are increasingly recognised, offering opportunities to intervene with medications directed specifically to food components, receptors and potentially the microbiome. Although the evidence supporting interventions for each mechanism is not at the same level of proof, the current state-of-the-art provides the opportunity to advance the practice from treatment based on symptoms to individualisation of treatment guided by pathophysiology and clinically identified biomarkers. Conclusion These advances augur well for the implementation of evidence-based individualised treatment for patients with IBS based on actionable biomarkers or psychological disturbances. All data relevant to the study are included in the article.
·gut.bmj.com·
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers